Kaigene, Inc. — SEC Form D Filing
Kaigene, Inc. filed an SEC Form D on October 14, 2026, reporting $54.96M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 14, 2026
- Amount reported
- $54.96M
- Round stage
- Series B+
- Industry
- Biotechnology
- Website
- https://kaigene.com/en/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients suffer from severe autoimmune diseases where current treatments often only manage symptoms, leaving a significant unmet medical need for therapies that address the underlying cause.
Solution
Kaigene develops next-generation antibody therapeutics and novel modalities that target and eliminate pathogenic autoantibodies and regulate immune overactivity to treat autoimmune diseases.
Verdict
Investors committed to Kaigene due to the large, known unmet need within autoimmune disease and the established precedent for significant returns from antibody-based therapies in this category, not because of a truly novel therapeutic approach that redefines standard of care. They were implicitly betting on the company's ability to navigate the complex clinical development path for biologics and capture market share from existing symptom-management treatments. Upside was inherently limited by the crowded development pipeline in autoimmune antibodies and the high capital intensity required to bring such therapies to market, constraining exit velocity and potential market dominance.
Source: SEC EDGAR Form D filing